Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

第1相 実施中（募集終了） NCT02208362

概要

This phase I trial studies the side effects and best dose of genetically modified T-cell immunotherapy in treating patients with malignant glioma that has come back (recurrent) or has not responded to therapy (refractory). A T cell is a type of immune cell that can recognize and kill abnormal cells in the body. T cells are taken from the patient's blood and a modified gene is placed into them in the laboratory and this may help them recognize and kill glioma cells. Genetically modified T-cells may also help the body build an immune response against the tumor cells.

Number of Participants With Grade 3 or Higher Toxicity Related to CAR T Cells

An average of 11 months · Participants

Number of Participants Experiencing a Dose Limiting Toxicity (DLT)

Up to 1 week following the last course, up to a total of 4 weeks (not including optional courses 4-6) · Participants

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
• Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
• TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
• Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
• A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care — Bryan Allen
• Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed M — National Cancer Institute (NCI)

すべての治験